Hexarelin
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
Key Takeaway
Hexarelin is a synthetic hexapeptide and the most potent growth hormone releasing peptide (GHRP) by raw GH output, producing larger GH pulses than GHRP-2, GHRP-6, or ipamorelin at equivalent doses (PMID: 9467542). It shares the core GHRP mechanism, acting as a full agonist at the ghrelin receptor (GHS-R1a) to stimulate pituitary GH release, but its higher receptor binding affinity and potency also produce the steepest desensitization curve and the most pronounced cortisol and prolactin elevation in the class.
These tradeoffs make hexarelin a specialized compound: its peak GH output is useful for short-burst protocols where maximum GH exposure over a 4 to 8 week window is the goal, but it is unsuitable for longer cycles because receptor desensitization progressively blunts its GH-stimulating response (PMID: 7671860). Beyond its GH-stimulating properties, hexarelin has attracted research interest for cardioprotective effects that appear to operate through a GH-independent pathway, making it one of the few GHRPs with potential cardiac applications outside of GH optimization (PMID: 10594485).
| Type | Growth Hormone |
| FDA Status | Research Only |
| Evidence Level | Moderate |
| Typical Dose | 100-200 mcg per injection |
| Frequency | 1-2 times daily on an empty stomach |
| Cycle Length | 4-8 weeks maximum, followed by at least 4 weeks off for receptor recovery |
| Key Goals | muscle-growth, recovery, anti-aging |
How it works
Hexarelin binds the growth hormone secretagogue receptor type 1a (GHS-R1a) with the highest affinity of any synthetic GHRP, triggering a downstream phospholipase C signaling cascade that elevates intracellular calcium and stimulates pituitary somatotrophs to release growth hormone. The mechanism mirrors other GHRPs but at greater potency: hexarelin produces a larger GH pulse per unit dose than GHRP-2, GHRP-6, or ipamorelin, as confirmed in direct comparative studies using both perifused pituitary tissue and human subjects (PMID: 9467542). At the hypothalamic level, hexarelin also stimulates GHRH release and suppresses somatostatin, contributing to the amplified GH response. When co-administered with a GHRH analog, the synergistic GH pulse is proportionally larger than with other GHRPs, reflecting hexarelin's superior pituitary priming potency (PMID: 7671860).
The desensitization problem is central to hexarelin's pharmacology. GHS-R1a undergoes receptor internalization and downregulation with repeated agonist exposure, a process that occurs with all GHRPs but proceeds faster with hexarelin due to its high potency and receptor binding kinetics. Published data show that daily hexarelin administration produces measurable attenuation of the GH response within 2 to 4 weeks, with continued use further blunting the response. This is why hexarelin protocols are typically limited to 4 to 8 week cycles with mandatory recovery periods to allow receptor resensitization before the next cycle (PMID: 7671860).
Hexarelin's cardioprotective effects operate through a mechanism that is at least partially independent of GH. Research published in 2000 demonstrated that hexarelin reduced myocardial damage from ischemia-reperfusion injury in both normal and hypophysectomized (GH-deficient) rats, suggesting direct cardiac GHS-R1a activation contributes to the protective effect independently of GH secretion (PMID: 10594485). GHS-R1a is expressed in cardiomyocytes, and hexarelin binding at this receptor appears to activate intracellular survival signaling pathways including PI3K/Akt and ERK1/2, which reduce apoptosis during ischemic stress. This cardioprotective research has not been replicated in large human trials, but it distinguishes hexarelin from other GHRPs that have not demonstrated comparable cardiac effects.
Benefits
- Highest peak GH output of any injectable GHRP in head-to-head comparative studies, making it the strongest short-duration GH secretagogue available in the research context (PMID: 9467542)
- Synergistic GH amplification with GHRH analogs: when combined with CJC-1295 or modified GRF(1-29), hexarelin produces proportionally larger combined GH pulses than other GHRPs due to its superior pituitary priming potency (PMID: 7671860)
- Cardioprotective effects demonstrated in animal ischemia-reperfusion models operating at least partially through GH-independent direct cardiac GHS-R1a activation, reducing myocardial damage markers in both normal and GH-deficient animal models (PMID: 10594485)
- Rapid GH-mediated lipolysis during short cycles, as the high peak GH concentrations produced by hexarelin drive stronger acute lipolytic signaling than lower-potency GHRPs at equivalent injection volumes
- Recovery enhancement through high-amplitude GH pulses that elevate IGF-1, support collagen synthesis, and accelerate protein turnover in muscle and connective tissue
- Useful as a short-cycle "reset" protocol after extended ipamorelin or GHRP-2 use, where its superior potency can overcome partial receptor downregulation that may have occurred with prolonged lower-potency GHRP exposure
- Moderate appetite stimulation, more than ipamorelin but less intense and more manageable than GHRP-6, making it easier to time around meals than the original GHRP
Clinical comparisons
Hexarelin sits at the top of the GHRP potency hierarchy for raw GH output, above GHRP-2, GHRP-6, and ipamorelin. However, this superior potency comes with the steepest side effect profile and the fastest desensitization curve, making it unsuitable as a long-term protocol compound. GHRP-2 produces strong GH stimulation with moderate cortisol and prolactin elevation and slower desensitization, making it a better choice for 10 to 12 week cycles.
Ipamorelin is the most selective GHRP, producing meaningful GH pulses with negligible cortisol and prolactin changes and no appetite stimulation, and can be used in longer cycles without desensitization concerns. GHRP-6 occupies a similar side effect burden to hexarelin but with less raw GH potency and more pronounced appetite stimulation. Among all GH secretagogues, hexarelin is the only compound with published cardioprotective research through a GH-independent cardiac receptor mechanism, which is unique in the class.
Side effects
- Fastest desensitization of any GHRP: GH response attenuation begins within 2 to 4 weeks of daily use and progresses with continued administration, limiting effective cycle length to 4 to 8 weeks. Post-cycle receptor recovery typically requires 4 weeks of abstinence before sensitivity is restored (PMID: 7671860)
- Significant cortisol elevation: Hexarelin produces the most pronounced cortisol increases of any GHRP class member at equivalent doses, through direct GHS-R1a activation in adrenocortical cells. This cortisol burden is a primary reason to prefer ipamorelin or GHRP-2 for longer protocols where cumulative cortisol exposure is a concern
- Significant prolactin elevation: Prolactin rises substantially with each hexarelin injection through GHS-R1a activation on pituitary lactotrophs. Chronic prolactin elevation increases gynecomastia risk in men and may cause menstrual irregularities in women with sustained high-dose protocols
- Water retention: High-amplitude GH pulses drive more pronounced fluid retention than lower-potency GHRPs, with associated bloating and peripheral edema that can be cosmetically significant in the first few weeks of use
- Appetite stimulation: Moderate and predictable, beginning 15 to 30 minutes post-injection. More manageable than GHRP-6 but more noticeable than ipamorelin. Timing injections before meals is the standard mitigation approach
- Injection site reactions: Localized redness and mild swelling at subcutaneous injection sites, similar to other GHRPs. Rotating injection sites across the abdomen reduces cumulative site irritation
- Risk of diminishing returns with early cycle extension: Users who extend hexarelin cycles beyond 8 weeks typically report progressively weaker GH responses, indicating receptor downregulation that will require a full break to reverse rather than dose escalation
Dosing protocol
Typical Dose
100-200 mcg per injection
Frequency
1-2 times daily on an empty stomach
Cycle Length
4-8 weeks maximum, followed by at least 4 weeks off for receptor recovery
Inject subcutaneously, typically into the abdomen, at least 2 hours after a meal. Wait 20 to 30 minutes before eating to avoid insulin-driven blunting of the GH response. Because hexarelin desensitizes faster than other GHRPs, most research protocols limit injection frequency to 1 to 2 times daily rather than the 3 times daily used with GHRP-2 or ipamorelin. The most effective timing windows are morning (fasted upon waking) and pre-sleep (2 hours after the last meal), capturing the natural GH pulse that accompanies slow-wave sleep onset. Stacking with a GHRH analog such as CJC-1295 or modified GRF(1-29) amplifies the GH response substantially and is standard practice when maximum GH output is the goal. The short recommended cycle length is a hard constraint rooted in receptor biology, not a conservative estimate. Users who try to extend hexarelin cycles beyond 8 weeks consistently report declining effectiveness that does not improve with dose increases. A 4-week minimum break between cycles is necessary to allow GHS-R1a receptor resensitization before the next cycle begins.
Deeper on Hexarelin
Full breakdowns of every part of the Hexarelin research base.
What you will need
Basic supplies for reconstitution and subcutaneous injection.
This page contains affiliate links. Learn more
Bacteriostatic Water (30mL)
$8-15Required for reconstituting lyophilized peptides. 30mL is standard.
Insulin Syringes (1mL, 29ga)
$12-20 (100ct)1mL insulin syringes with 29-gauge needles for subcutaneous injection.
Alcohol Prep Pads
$5-10 (200ct)Sterile 70% isopropyl alcohol wipes for injection site prep.
Sharps Container
$8-15FDA-cleared sharps disposal container for used needles.
Get the Hexarelin cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Key research
Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, before and during somatostatin infusion and after exogenous somatostatin and GHRH in humans
Journal of Clinical Endocrinology and Metabolism (1994) — PubMed
Established hexarelin's superior GH-stimulating potency in healthy human subjects and characterized its interaction with somatostatin and GHRH, demonstrating the somatostatin-suppressing component of its mechanism. Also documented the desensitization pattern with repeated administration that defines hexarelin's short cycle requirement.
Comparison of growth hormone (GH)-releasing peptides: stimulation of GH release from perifused rat anterior pituitaries by GHRP-1, GHRP-2, GHRP-6, hexarelin, and MK-0677
Endocrinology (1997) — PubMed
Direct head-to-head comparison across the GHRP class in perifused pituitary tissue confirmed hexarelin produces the highest peak GH response among injectable GHRPs, establishing its position as the most potent member of the class and the comparative potency hierarchy used in research and clinical contexts.
Hexarelin peptide: a growth hormone-releasing peptide with cardioprotective activity
Proceedings of the National Academy of Sciences (2000) — PubMed
Demonstrated hexarelin reduced myocardial damage from ischemia-reperfusion injury in animal models through a mechanism partially independent of GH secretion, providing evidence for direct cardiac GHS-R1a activation as a cardioprotective pathway. This study established hexarelin as the only GHRP with documented GH-independent cardiac effects.
Real-world data
Research community experience with hexarelin is consistent with the clinical literature. Users confirm that the first 3 to 4 weeks of a hexarelin cycle produce noticeably stronger GH effects than any other GHRP, including significantly more pronounced water retention, sleep improvement, and body composition changes. By weeks 6 to 8, most users report a clear weakening of effects even without changing dose, which aligns with the documented desensitization kinetics.
Users who attempt to dose 3 times daily with hexarelin (as they might with GHRP-2) report faster desensitization and more pronounced cortisol effects without proportional GH benefit. The 1 to 2 times daily protocol with strict cycle length adherence is the consistent recommendation from experienced research users. Cardioprotective effects are not observable subjectively, but the research is frequently cited as a secondary reason for choosing hexarelin in older or cardiovascular-risk populations.
Get the Hexarelin cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Frequently asked questions
Why can't hexarelin be used in longer cycles like GHRP-2 or ipamorelin?
Hexarelin's higher receptor binding potency accelerates GHS-R1a receptor internalization and downregulation with repeated exposure. This desensitization process begins within 2 to 4 weeks and progressively reduces GH output even without changing the dose. The receptor requires approximately 4 weeks without hexarelin stimulation to restore its baseline sensitivity. Longer cycles simply produce diminishing returns rather than sustained GH stimulation, which is why the 4 to 8 week maximum is not a conservative estimate but a reflection of the underlying receptor biology.
Is hexarelin's cardioprotective effect clinically meaningful?
The cardioprotective research is real and published in a high-credibility journal (PNAS), but it comes from animal models and has not been replicated in large human trials. The mechanism, direct cardiac GHS-R1a activation independent of GH secretion, is plausible and interesting, but extrapolating from animal ischemia-reperfusion models to human cardiovascular outcomes requires caution. The research supports further investigation rather than confident clinical application. It does distinguish hexarelin from other GHRPs, none of which have comparable cardiac receptor data.
How does hexarelin compare to high-dose ipamorelin for someone seeking maximum GH stimulation?
Hexarelin produces larger absolute GH pulses at equivalent doses than ipamorelin and desensitizes GHS-R1a faster. Ipamorelin at high doses can increase GH output, but its receptor selectivity means less cortisol and prolactin elevation regardless of dose, and its desensitization profile is more favorable for longer protocols. For a maximum short-burst GH effect over 4 to 6 weeks, hexarelin is superior. For sustained GH optimization over 10 to 16 weeks with a cleaner hormonal profile, ipamorelin is the better tool.
Does hexarelin cause as much appetite stimulation as GHRP-6?
No. Hexarelin produces moderate appetite stimulation, meaningfully less than GHRP-6. The hunger signal is noticeable and begins within 15 to 30 minutes of injection but is generally described as manageable and easy to time around meals. GHRP-6's appetite effect is substantially more intense and persistent, driven by its particularly strong ghrelin-mimetic activity at hypothalamic hunger centers.
Can hexarelin be stacked with other GHRPs?
Stacking hexarelin with another GHRP adds little GH benefit because both peptides act on the same receptor, and combining two GHS-R1a agonists accelerates desensitization without producing synergistic GH output. The high-value combination is hexarelin plus a GHRH analog (CJC-1295 or modified GRF(1-29)), because these work through complementary mechanisms: hexarelin at GHS-R1a and the GHRH analog at the GHRH receptor on the same pituitary somatotroph cells. This combination produces the largest GH pulses achievable with peptide protocols.
Related peptides
Looking for weight loss peptides? See our complete guide to the best peptides for weight loss or compare semaglutide vs tirzepatide .
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol.